drugset / Trial / NCT01348737

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

NCT01348737 ↗

Phase 1 Completed 72 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of the study is to assess the safety, tolerability and blood concentration of AZD3839 following oral administration of single doses in healthy men and women of non-childbearing potential

Timeline

Start
2011-06
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD3839 Small molecule — Oral

Indications